170 related articles for article (PubMed ID: 10625946)
1. Phytate (IP6) is a powerful agent for preventing calcifications in biological fluids: usefulness in renal lithiasis treatment.
Grases F; Costa-Bauzá A
Anticancer Res; 1999; 19(5A):3717-22. PubMed ID: 10625946
[TBL] [Abstract][Full Text] [Related]
2. Urinary lithogen risk test: usefulness in the evaluation of renal lithiasis treatment using crystallization inhibitors (citrate and phytate).
Conte A; Pizá P; García-Raja A
Arch Esp Urol; 1999; 52(1):94-9. PubMed ID: 10101897
[TBL] [Abstract][Full Text] [Related]
3. Urinary lithogen risk test: usefulness in the evaluation of renal lithiasis treatment using crystallization inhibitors (citrate and phytate).
Conte A; Pizá P; García-Raja A; Grases F; Costa-Bauzá A; Prieto RM
Arch Esp Urol; 1999 Apr; 52(3):305-10. PubMed ID: 10371752
[TBL] [Abstract][Full Text] [Related]
4. Effects of inositol hexaphosphate (phytate) on calcium binding, calcium oxalate crystallization and in vitro stone growth.
Saw NK; Chow K; Rao PN; Kavanagh JP
J Urol; 2007 Jun; 177(6):2366-70. PubMed ID: 17509360
[TBL] [Abstract][Full Text] [Related]
5. Study of a myo-inositol hexaphosphate-based cream to prevent dystrophic calcinosis cutis.
Grases F; Perelló J; Isern B; Prieto RM
Br J Dermatol; 2005 May; 152(5):1022-5. PubMed ID: 15888163
[TBL] [Abstract][Full Text] [Related]
6. Key Aspects of Myo-Inositol Hexaphosphate (Phytate) and Pathological Calcifications.
Grases F; Costa-Bauza A
Molecules; 2019 Dec; 24(24):. PubMed ID: 31817119
[TBL] [Abstract][Full Text] [Related]
7. Factors affecting the regrowth of renal stones in vitro: a contribution to the understanding of renal stone development.
Costa-Bauzá A; Isern B; Perelló J; Sanchis P; Grases F
Scand J Urol Nephrol; 2005; 39(3):194-9. PubMed ID: 16118089
[TBL] [Abstract][Full Text] [Related]
8. Urinary phytate in calcium oxalate stone formers and healthy people--dietary effects on phytate excretion.
Grases F; March JG; Prieto RM; Simonet BM; Costa-Bauzá A; García-Raja A; Conte A
Scand J Urol Nephrol; 2000 Jun; 34(3):162-4. PubMed ID: 10961468
[TBL] [Abstract][Full Text] [Related]
9. Dietary myo-inositol hexaphosphate prevents dystrophic calcifications in soft tissues: a pilot study in Wistar rats.
Grases F; Perelló J; Prieto RM; Simonet BM; Torres JJ
Life Sci; 2004 May; 75(1):11-9. PubMed ID: 15102518
[TBL] [Abstract][Full Text] [Related]
10. Effects of phytate and pyrophosphate on brushite and hydroxyapatite crystallization. Comparison with the action of other polyphosphates.
Grases F; Ramis M; Costa-Bauzá A
Urol Res; 2000 Apr; 28(2):136-40. PubMed ID: 10850638
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of Mixtures of Magnesium, Citrate and Phytate as Calcium Oxalate Crystallization Inhibitors in Urine.
Grases F; Rodriguez A; Costa-Bauza A
J Urol; 2015 Sep; 194(3):812-9. PubMed ID: 25818031
[TBL] [Abstract][Full Text] [Related]
12. Phytate acts as an inhibitor in formation of renal calculi.
Grases F; Isern B; Sanchis P; Perello J; Torres JJ; Costa-Bauza A
Front Biosci; 2007 Jan; 12():2580-7. PubMed ID: 17127264
[TBL] [Abstract][Full Text] [Related]
13. Factors affecting calcium oxalate dihydrate fragmented calculi regrowth.
Costa-Bauzá A; Perelló J; Isern B; Sanchis P; Grases F
BMC Urol; 2006 Jul; 6():16. PubMed ID: 16822299
[TBL] [Abstract][Full Text] [Related]
14. Phytate Dephosphorylation Products Also Act as Potent Inhibitors of Calcium Oxalate Crystallization.
Grases F; Costa-Bauzá A; Calvó P; Julià F; Dietrich J; Gomila RM; Martorell G; Sanchis P
Molecules; 2022 Aug; 27(17):. PubMed ID: 36080228
[TBL] [Abstract][Full Text] [Related]
15. Phytate inhibits bovine pericardium calcification in vitro.
Grases F; Sanchis P; Costa-Bauzá A; Bonnin O; Isern B; Perelló J; Prieto RM
Cardiovasc Pathol; 2008; 17(3):139-45. PubMed ID: 18402805
[TBL] [Abstract][Full Text] [Related]
16. Plant phosphates, phytate and pathological calcifications in chronic kidney disease.
Buades Fuster JM; Sanchís Cortés P; Perelló Bestard J; Grases Freixedas F
Nefrologia; 2017; 37(1):20-28. PubMed ID: 27697413
[TBL] [Abstract][Full Text] [Related]
17. Effect of Phytate (InsP6) and Other Inositol-Phosphates (InsP5, InsP4, InsP3, InsP2) on Crystallization of Calcium Oxalate, Brushite, and Hydroxyapatite.
Calvó P; Costa-Bauza A; Grases F
Biomolecules; 2023 Jun; 13(7):. PubMed ID: 37509097
[TBL] [Abstract][Full Text] [Related]
18. Uric acid as inducer of calcium oxalate crystal development.
Grases F; Sanchis P; Isern B; Perelló J; Costa-Bauzá A
Scand J Urol Nephrol; 2007; 41(1):26-31. PubMed ID: 17366099
[TBL] [Abstract][Full Text] [Related]
19. Exploring the Potential Relationship Between Phytate Ingestion, Urinary Phytate Excretion, and Renal Stone Risk in a Unique Human Model: No Hard Evidence in Support of Phytate as a Stone Inhibitor.
Fakier S; Rodgers A
J Ren Nutr; 2020 Sep; 30(5):396-403. PubMed ID: 31928801
[TBL] [Abstract][Full Text] [Related]
20. Inositol hexaphosphate (IP6) as an anti-neoplastic and lipid-lowering agent.
Jariwalla RJ
Anticancer Res; 1999; 19(5A):3699-702. PubMed ID: 10625943
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
